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Nimotuzumab is an anticancer agent which belongs to the inhibitor group of 
Epidermal Growth Factor Receptor (EGFR). This monoclonal antibody has a 
relatively high molecular weight which makes slow penetration on tumor cell, as 
concequence, it is less attractive in imaging kinetics, and potentially elicits 
antibodies respons. Therefore in this study nimotuzumab was fragmented to form 
bivalent antibody [F(ab’)2] and then labeled with 
125I to form 125I-F(ab’)2-
nimotuzumab which can be used further as a precursor for preparing 125I-F(ab’)2-
nimotuzumab-NLS (NLS =  nuclear localizing sequences ) radiopharmaceutical for 
radioimmunotherapy. The aims of this study were to obtain  characteristics of 125I-
F(ab’)2-nimotuzumab by comparing with the 
125I labeled-intact nimotuzumab (125I-
nimotuzumab). This study was initiated by purifying nimotuzumab by mean of 
dialysis. The purified nimotuzumab was then fragmented by using pepsin. The 
F(ab')2-nimotuzumab formed was then purified from its by-products which formed 
in fragmentation process by using a PD-10 column (consisted Sephadex G25).  The 
intact nimotuzumab and its F(ab’)2 fragment were then labeled with the 
125I to form 
125I-nimotuzumab and 125I-F(ab’)2-nimotuzumab. The radiochemical purity are 
98.27 % and 93.24 % ,respectively. Stability test results show that, both of 125I-
nimotuzumab and 125I-F(ab’)2-nimotuzumab more stable at 4 °C than at room 
temperature storage and 37 °C. 
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INTRODUCTION 
 
One of the public health problems in the 
world included in Indonesia is cancer. Every year, 
cancer patients in the world reached 12 million 
people and 7.6 million of them died. Therefore we 
need an appropriate control action, if it is not carried 
out  then in 2030 the estimated 26 million people 
will suffer from cancer and 17 million of them will 
die from the disease [1].  
Considering the high number of cancer 
patients in Indonesia. it is necessary to develop 
effective treatments to kill the cancer cells. One of  
treatment that has been developed at this time is an 
                                                 
 Corresponding author. 
   E-mail address: r_dini@batan.go.id 
anti-cancer therapies using monoclonal antibodies. 
The anti-cancer therapies work by eliminating 
cancer cells without damaging normal cells to 
excess because targeting the specific markers 
expressed by cancer cells [2]. 
For almost three decades, antibodies have 
been used in medicine for imaging and therapeutic 
purposes because of their selectivity towards 
specific targets [3]. At least 19 monoclonal 
antibodies (mAb) in the market that have been 
approved by the FDA. More than 150 of  its in 
clinical development [4]. However, still there is an 
obstacle in the use of mAb which is due to its large 
size molecular weight. Monoclonal antibodies 
(mAbs) has large size (molecular weight of ~ 150 
kDa) thus causing penetrate slowly and need long 
time in the blood circulation (days to weeks) [5].             
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In order to overcome that obstacle a smaller size of 
mAb which maintains all its property would be 
desirable. 
R.S. Stowers, J.A. Callihan, & J.D. Bryers [6] 
reported that antibody fragment reduces steric 
hindrance and gives better tissue penetration which 
lead to be be a more sensitive antigen detection. 
Furthermore,antibody fragment also has reduced 
non-specific binding and lower immunogenicity in 
vivo. According to T.M Behr, et al. [7] the 
advantages of small antibody fragments such as      
F(ab’)2 is that its accumulation in tumor cells will be 
faster and more homogeneous. In this study, when 
compared to the use of intact nimotuzumab which 
has greater molecular weight, nimotuzumab 
fragments (F (ab’)2-nimotuzumab) with a smaller 
molecular weight is expected to increase its 
effectiveness in cancer treatment. 
Nimotuzumab is a humanized mAb that 
inhibits EGF binding because it binds to the 
extracellular domain of the EGFR [8]. 
Nimotuzumab has been approved in several 
countries for the treatment of  glioma as well as 
head and neck tumors [9]. Nimotuzumab is in 
clinical trials for various tumor types including 
prostate, glioma (pediatric and adult), colorectal, 
pancreatic, breast cancer, non–small cell lung, 
cervical, and esophageal [8]. Moreover, it was 
reported that  nimotuzumab had been found to have 
higher therapeutic effect when combined with the 
external radiation therapy [10].  
The  aims  of  this  preliminary  study were to 
prepare 
125
I-F(ab’)2-nimotuzumab and to obtain  
characteristic data of 
125
I-F(ab’)2-nimotuzumab 
which was then compared with the 
125
I-labeled-
intact nimotuzumab (
125
I-nimotuzumab). Next study 
in the near future will modify this 
125
I-F(ab’)2-
nimotuzumab by conjugating it with NLS to prepare 
125
I-F(ab’)2-nimotuzumab-NLS as a therapeutic 
radiopharmaceutical. A typical NLS peptide motif 
containing a cluster of four or more cationic 
residues of lysine (K) or arginine (R) enables the 
radiopharmaceutical to be in close proximity to 
the DNA so that the nanometer-range Auger 
electrons emitted by 125I can cause DNA damage 
of cancer cells [11]. 
 
 
EXPERIMENTAL METHODS 
 
Material used in this study included 
Nimotuzumab/TheraCIM obtained from Kalbe 
Farma.  Na
125
I was prepared by irradiating 
124
Xe in 
G.A. Siwabessy Multi Purpose Reactor to produce 
125
Xe which decayed to 
125
I. I-125 was then 
recovered and processed at the Radioisotope and 
Radiopharmaceutical Centre, National Nuclear 
Energy of Indonesia (RRC – NNEI) to produce 125I.  
Pepsin from porcine gastric mucosa purchaced from 
Sigma-Aldrich. Monobasic sodium phosphate 
(NaH2PO4.H2O), dibasic sodium phosphate 
(Na2HPO4.2H2O), trizma base, tris-glycine, bovine 
serum albumin, acrylamide, bis-acrylamide, sodium 
dodecyl sulfate, coomassie blue and bromphenol 
blue tetramethylethylenediamine (TEMED) were 
obtained from Sigma. Methanol, chloroform and 
sodium acetate were obtained from E. Merck. All  
chemical reagen that used in this study are pro 
analysis. Protein standart and protein dye were 
purchaced from Bio-Rad and Iodogen from Pierce. 
Saline solution and aquabidest sterile were obtained 
from IPHA.  Dialysis cassettes (20 KDa molecular 
weight cut-off, MWCO) were obtained from Thermo 
Scientific, PD10 Sephadex G-25 Columns were 
purchaced from GE Healthcare and Whatman paper 
No.1 from E.Merck.  
Equipment used for analysis are included high 
performance liquid chromatography, HPLC 
(Shimadzu) equipped with a size exclusion   
columns (SEC) BioSuite 250 column (Waters) and 
an UV-Vis detector (Shimadzu), termomixer 
(Eppendorf), mini-Protean 3 cell (Bio-Rad), gamma 
counter (Nucleus), centrifuge (Beckman Coulter), 
dose calibrator (Capintec), and plate reader 
(BioTek). 
 
 
Nimotuzumab dialysi 
  
Nimotuzumab was firstly purified from its 
excipients by dialysis. Nimotuzumab was injected 
onto a dialysis cassette (20 KDa molecular weight 
cut-off) and the cassete was then dialysed with 
sodium acetate, pH 4.5. This process was carried out 
at 4 ºC  with three times buffer changes for 72 hours 
[12]. The dialysed nimotuzumab was  analyzed by 
using high performance liquid chromatography 
(HPLC) equiped with SEC Biosuite 250 column and 
UV-Vis detector. 
 
 
Optimization of F(ab’)2-nimotuzumab 
 
Pepsin (0.75 mg) was dissolved in 100 µL 0.02 
M sodium acetate pH 4.5 which was then added into                 
3 mL of dialyzed nimotuzumab (5 mg/ mL). The 
mixture was mixed and heated by using termomixer at 
37 °C for 14 hours.  Samples were taken at 0, 3, 6, 
9,12, 13, and 14 hours.  To each sample was added 
Tris-HCl 10 mM, pH 8.0 to stop fragmentation 
process. The samples were then analyzed by sodium 
dedocyl sulfate- polyacrylamide gel electrophoresis 
(SDS-PAGE). Running buffer pH 8.3 used in this 
analysis [13].  
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Purification of F(ab’)2-Nimotuzumab 
 
Purification of F(ab’)2-nimotuzumab was 
carried using a PD-10 column.  Aliquot of raw 
product (mixture of fragmented nimotuzumab, 
F(ab’)2 and Fc) was loaded onto a PD-10 column 
pre-blocked and pre-equilibrated with 500 µL 10% 
BSA and 0.01 M PBS pH 7.4 respectively.  The 
column was then eluted with 0.01 M PBS pH 7.4 
[12].  The resulting eluent was collected in 0.5 mL 
fraction and its purity was analyzed using HPLC. 
 
 
Preparation of 125I-F(ab’)2-Nimotuzumab  
 
The purified Nimotuzumab fragment (F(ab’)2-
Nimotuzumab) was radiolabelled with Na
125
I using 
Iodogen method.  The reactant molar ratio was 1: 
100: 2 for F(ab’)2-Nimotuzumab : iodogen : 
potassium iodide respectively. The iodination 
process was initiated by dissolving  the Iodogen in 
chloroform in a test tube.  It was then dried using 
nitrogen gas at room temperature to form a tiny 
layer Iodogen on the surface of the test tube.  
Solution of F(ab’)2-Nimotuzumab was then  added 
to the test tube which was then was stirred using a 
vortex which was followed by addition of 
125
I              
and potassium iodide. The mixture was                    
stirred and then left to incubate for 2 minutes.  The 
same procedure was also performed for labeling  
intact nimotuzumab with
125
I  [14 with modification].  
 
 
Purification of 125I-F(ab’)2-Nimotuzumab 
 
125
I-F(ab’)2-Nimotuzumab was purifed from 
its impurities, free 
125
I by using a gel filtration 
column  (PD-10) [7]. The reaction mixture from 
radiolableling process was loaded onto a PD-10 
column pre-blocked and pre-equilibrated with               
500 µL 10% BSA and 0.01 M PBS pH 7.5. The 
column was then eluted using 0.01 M phosphate 
buffer pH 7.5.  The eluent was collected in 0.25 mL 
fraction (up to 50 fraction).  Radioactivity of each 
fraction was then measured by using a dose 
calibrator.  Fractions which have high radioactivity 
were then tested for their radiochemical purity by 
means of  paper chromatography. 
 
 
Determination radiochemical purity of  
125I-F(ab’)2-Nimotuzumab 
 
Radiochemical purity of 
125
I-F(ab’)2-
Nimotuzumab was determined by using paper 
chromatography with Whatman paper No.1           
(1.5 x 15 cm) and 85% methanol as stationary and 
mobile phases respectively [15]. An aliquot of 
reaction mixture was spotted 2 cm from the bottom 
of the strip. The strip was cut into 1 cm portion and 
the radioactivity of each portion was measured 
using a gamma counter. The radiochemical purity of 
125
I-F(ab’)2-Nimotuzumab  was calculated based on 
the ratio of the count rate of 
125
I-F(ab’)2-
Nimotuzumab fraction with the total count rate.The 
same procedure was also performed to determine the 
radiochemical purity of 
125
I-Nimotuzumab.  
 
 
Stability test of 125I-F(ab’)2- nimotuzumab 
(stored at room temperature, 37 °C and 4 °C) 
 
The stability of 
125
I-F(ab’)2- nimotuzumab 
which was stored at room temperature, 37 °C and   
at 4 °C were monitored using an using a paper 
chromatography with Whatman paper No.1 (1.5 x 
15 cm) and 85% methanol as stationary and mobile 
phases respectively  At set intervals (1, 3, 5 days),             
2 µl sample was taken and spotted on  Whatman 
paper No. 1 and developed in 85% methanol. The 
radiochemical purity of 
125
I-F(ab’)2-nimotuzumab 
was similar to the above-mentioned procedure [12].  
 
 
RESULTS AND DISCUSSION 
 
The initial phase of this study  is dialysis 
process, in order to purify the sample nimotuzumab 
of excipients contained in it. The results were then 
analyzed using HPLC. To compare chromatograms 
profiles, analysis was performed on samples 
nimotuzumab before and after dialysis.          
Dialysis cassette used has a molecular weight cut off 
20,000 Da, which means that substances having a 
molecular weight below 20 000 Da would be out of 
the membrane cassette while those having a 
molecular weight above 20,000 will retained in the 
membrane. Nimotuzumab has a molecular weight of 
150,000 Da [16], that remain in the membrane 
cassettes. While excipients such as sodium 
phosphate dibasic (143 Da), monobasic sodium 
phosphate (142 Da), sodium chloride (58.5 Da) and 
polysorbate 80 (1309 Da) which has a molecular 
weight below 20,000 Da would be out of membrane 
cassettes. The results of the analysis using HPLC 
(Fig. 1) showed that there was no significant 
difference in nimotuzumab before and  after 
dialysis. The retention times were  6.683 and 6.667 
mins before and after dialysis respectively. The 
excipients having very low molecular weight were 
not appear because their peaks were to small as 
compared to the main substance (i.e. nimotuzumab). 
These phenomena might be due to low 
concentrations and/ or lack of chromophore which 
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[?] 
are able in absorbing UV light in the excipients 
which in turned giving no absorbances/ peaks in the 
chromatogram. 
 
 
 
 
 
(a) 
 
 
 
 
(b) 
 
Fig. 1. (a) Nimotuzumab chromatograms before dialysis,          
(b) Nimotuzumab chromatograms after dialysis. 
 
 
To determine whether nimotuzumab sample 
has a molecular weight 150,000 Da, the comparative 
form of standard proteins used. This standard was 
also analyzed using HPLC to determine its 
chromatogram. The results of the standard protein 
chromatograms presented in Fig. 2.  
 
 
 
 
 
 
Fig. 2. Protein standard chromatogram. 
It can bee seen in Fig. 2 there are five peaks 
that are associated with standard protein which 
consisted of thyroglobulin (670,000 Da), γ-globulin 
(158,000 Da), ovalbumin (44,000 Da), mioglobulin 
(17,000 Da) and vitamin B12 peak (1,350 Da) with 
retention time (Rt) of 4.907, 6.907, 8.013, 9.680, 
12.160 mins respectively.  These Rts are meet     
with basic principle of SEC column used, where a 
large molecules will be the first to be eluted        
from the column because a large molecule passing 
the sidelines gel, while smaller molecules will elute 
more slowly as it enters the pores of the gel [17].  
Based on these data, the positions of nimotuzumab 
which has a molecular weight of 150,000 Da           
with a retention time of 6.667 min is almost the 
same as the γ-globulin which had a retention        
time of 6.337 min with a molecular weight of 
158,000 Da. This suggests that the initial         
sample nimotuzumab which will be used in this 
study has a molecular weight corresponding to the 
reference. 
After the dialysis process, the next step is the 
fragmentation of nimotuzumab using pepsin. 
Monoclonal antibodies such as nimotuzumab 
comprises two antigen-binding fragments (Fab) that 
linked to the constant fragment (Fc) by a flexible 
polypeptide chain called the hinge region. Each Fab 
fragment is formed by two pairs of polypeptide 
chains, namely the heavy chain and light chain [18]. 
Pepsin can be used to cleave  immunoglobuline 
(IgG)  molecules at the C-terminal side of the inter-
heavy-chain disulfides in the hinge region, 
producing a bivalent antigen binding fragment 
F(ab’)2 and an Fc fragment. The F(ab’)2 produced  
still be able to bind with the antigen because this 
form is bivalent. Furthermore, using this enzyme, 
most of the Fc fragments undergo extensive 
degradation and cannot be recovered intact [13,19]. 
By eliminating the Fc portion it also means 
removing the ability to bind to Fc receptors,    
thereby reducing the occurrence of non-specific 
interactions [3]. 
Nimotuzumab is a humanized antibody      
[8], this antibody consists of a small portion           
of mouse Fab that coupled with human antibodies 
(95-98%) [20]. Previous work reported that mouse 
IgG antibody and human antibody were fragmented 
with pepsin to produce F(ab)2 and Fc within           
24 hours and 12 hours respectively [13].                
To determine the optimum time for fragmentation   
of nimotuzumab, which has human and mouse 
component, incubation time  were varied from         
3, 6, 9, 12, 13 and 14 hours. Fig. 3 showed                    
the SDS-PAGE images of nimotuzumab with pepsin 
with fragmentation time varied from 3 up to              
14 hours.  
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Fig. 3. Time optimization of nimotuzumab fragmentation using 
pepsin. 
 
It can be seen in Fig. 3  that the initial 
position of the intact nimotuzumab was between 
two protein standard with molecular weights                    
of 118,579 Da and 211,475 Da. After the addition      
of  pepsin, the expected molecular weight is                  
about 100,000 Da. Based on the optimization                
time of fragmentation, it was known that                          
the incubation time for completing the 
fragmentation of all intact nimotuzumab was 14 
hours. It is shown as there was no more protein    
band at the position of  intact nimotuzumab.              
When compared to protein standard,  position of 
fragment nimotuzumab  located between molecular 
weight 79,995 Da and 118,579 Da. It means that              
is in compliance with the expected molecular 
weight. So it can be determined that the                     
time fragmentation of nimotuzumab to produce 
fragments F(ab’)2 was 14 hours. 
 
 
 
 
 
 
 
Fig. 4. Chromatogram of  F(ab’)2-nimotuzumab before 
purification.  
As shown by the SDS-PAGE results, 
fragmentation process of nimotuzumab with pepsin 
produce not only F(ab)2 fragment but also by-
products such Fc.  Chromatogram of the above 
mentioned raw product which was also analysed 
with HPLC equipped with SEC BioSuite 250 
column (Waters) and an UV-Vis detector 
(Shimadzu) is presented in Fig. 4. 
The chromatogram clearly showed several 
peaks with Rts of 7.363, 10.040, 10.547, 11.360 and 
13.057 mins.  The peaks with Rt 7.363 mins was 
expected to be F(ab)2-nimotuzumab ( ~ 100,000 Da) 
as its Rt is betwen Rt of γ-globulin 6.907 mins 
(158,000 Da) and ovalbumin 8,013 min (44,000 Da) 
as presented in Fig. 2.  Profile chromatograms 
before purification is needed to determine the 
effectiveness of the purification performed.          
The purification method used to separate F(ab’)2 
with Fc is filtration using PD-10 column of 
Sephadex G-25. 
In order to purify F(ab)2 from other by-
products, raw product of fragmented nimotuzumab 
was passed through a PD 10 column (consist of 
Sephadex G25 M) pre-blocked and pre-equilibrated 
with 500 µL 10% BSA and 0.01 M PBS pH 7.4 
respectively. Each of fraction from the retrived 
eluent (0.250 mL/ fraction) was then analysed with 
with HPLC equipped with SEC BioSuite 250 
column (Waters) and an UV-Vis detector 
(Shimadzu). Figure 5 shows a chromatogram of 
fragmented nimotuzumab  after purification process.  
It can be seen that purification process by using a 
PD-10 column was quite effective to eliminate by-
product such as Fc portion. 
 
 
 
 
 
Fig. 5. Chromatogram of F(ab’)2-nimotuzumab after 
purification. 
 
In addition to retention time, from analysis 
using HPLC, the percent areas of the samples were 
also obtained. Before purification there were five 
peaks with the percent area of F(ab’)2 was 54.5%. 
After the purification, there are two peaks with the 
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percent of area F(ab’)2  amounted to 94.7%. 
Although a small portion remained (Fc fragments = 
5.3%) in a purified fraction, but there has been an 
increase in the percentage purity of the fragment 
F(ab’)2, which is quite significant when compared to 
the prior column passed.  
The radioiodide used for labeling must be 
analyzed in its radiochemical purity before 
conjugated with nimotuzumab. To determine the 
radiochemical purity of Na
125
I was used paper 
chromatography (stationary phase : Whatman paper 
No. 1, mobile phase : methanol 85%). 
The radiochromatogram of Na
125
I was shown in 
Fig. 6 indicating that the radiochemical purity of 
Na
125
I was 97.78%. The requirements set by Medy 
Physic Inc. for radiochemical purity of I
-
  is not less 
than 95% [21]. Based on the reference, Na
125
I used in 
this study have met the requirements set for 
radiochemical purity and can be used for further 
studies. 
 
 
 
 
 
Fig. 6. Radiochromatogram of Na125I. A gamma counter was 
used in the fraction measurements. 
 
In this study, in addition to radiolabeling  of 
125
I-F(ab’)2-nimotuzumab, radiolabeling of the intact 
nimotuzumab was also performed as a comparison. 
Radiolabeling of F(ab)2-nimotuzumab and intact 
nimotuzumab with 
125
I was carried out by firstly 
oxidizing 
125
I with Iodogen to form 
125
I
+
. M.  Behe, M.  
Gotthardt, and T.M.  Behr reported that  a non reactive   
form like iodide (I
-
) must be  activated by  an  
oxidizing agent to a reactive cationic species  (I
+
) [22]. 
Its allows a spontaneous electrophilic substitution on 
phenolic aryl group of tirosin or  imidazole group of 
histidine. The radiolabelled F(ab)2-nimotuzumab and 
intact nimotuzumab were then purified from unreacted 
125
I
+
 and other impurities by using PD-10 column 
(consist of Sephadex G25 M pre-blocked and pre-
equilibrated with 500 µL 10% BSA and 0.01 M PBS 
pH 7.4 respectively). 
The graph of fraction 
125
I-nimotuzumab after 
passing through PD-10 columns is  shown in        
Fig. 7a, indicating that the fraction 14 is a fraction 
with the highest activity. It was assumed that  this 
fraction is a fraction that can form complexes 
125
I-
nimotuzumab with a maximum  radiochemical 
purity as compared to the other fractions. To prove 
the assumption, radiochemical purity was tested 
using paper chromatography. Then its activity was 
measured  using gamma counter, the measurement 
results are shown in Fig. 8a. Graph of Fraction     
125
I-F(ab’)2-nimotuzumab after passed the PD-10 
columns  shown in Fig. 7b. Based on that Figure,     
it was found that the fraction number of 15 is        
the fraction with the highest activity. Radiochemical 
purity of the fractions 15 
125
I-F(ab’)2-nimotuzumab 
was 93.24% (Fig. 8b). 
 
 
 
 
(a) 
 
 
 
(b) 
 
Fig. 7. Graph Fraction of 125I-nimotuzumab (a) and 125I-F(ab’)2-
nimotuzumab (b) after passed  the PD-10 column. A dose 
calibrator was used in the fraction measurements.  Eluent: 0.01 
M phosphate buffer pH 7.5.  
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(a) 
 
 
 
(b) 
 
 
Fig. 8. Radiochromatogram of fraction 14 125I-nimotuzumab   
(a) and fractions 15 125I-F(ab’)2-nimotuzumab (b) A gamma 
counter was used in the fraction measurements. 
 
As it can be seen on Fig. 8, that radiochemical 
purity of 
125
I-F(ab)2-nimotuzumab (93.14%) was 
found slightly lower compared to that of 
125
I-intact 
nimotuzumab (98.27%).  This might be attributed 
by the F(ab)2-nimotuzumab used in this experiment 
which had a purity of only 94.7% and impurity 
(other protein with a molecular weight < 100 KDa) 
of ~ 5.3% (Fig. 5).  When F(ab)2-nimotuzumab was 
radiolabelled this impurity was also radiolabelled.  
This can be seen in existence of tailing in 
chromatograms of purification of 
125
I-F(ab)2-
nimotuzumab from free 
125
I
+
 (Fig. 7b). 
To date there is no standard regarding the 
radiochemical purity limits allowed for monoclonal 
antibodies and/ or their fragments radiolabeled with 
125
I.  However, several reports as follow might be 
used as a guide.  Wen-sheng Huang et al., [23] used 
125
I- and 
131
I-1H10 monoclonal antibody with 
radiochemical purity ≥ 90%.  While, United States 
Pharmacopeia (USP) 35 in 2012 states that 
radiochemical purity of albumin marked or 
radiolabelled with the 
125
I , may not be less than 
97% [24]. 
Stability test of 
125
I-F(ab’)2-nimotuzumab     
as well as 
125
I-nimotuzumab were performed in      
order to determine whether these complexes       
were stable in various storage temperatures (4 °C, 
room temperature and 37 °C). 
 
Table 1. Percentage of radiochemical purity 125I-F (ab’)2-
nimotuzumab and 125I-nimotuzumab at 3 variations storage 
temperature. 
 
Incubation % Radiochemical Purity 
Time (day) 125I-nimotuzumab 125I-F(ab’)2-nimotuzumab 
 
Room 
Tempe 
rature 
37 °C 4 °C 
Room 
Tempe 
rature 
37 °C 4 °C 
1 97.07 97.07 97.07 92.29 92.29 92.29 
3 96.70 95.40 96.55 79.81 83.91 86.98 
5 94.14 95.25 96.63 78.53 83.48 87.37 
 
It can be seen in Table 1 that both of          
125
I-F(ab’)2-nimotuzumab and 
125
I-nimotuzumab 
maintained their radiochemical purity when stored 
at any above-mentioned temperature for one day.  
However radiochemical purity both complexes 
started to decrease after incubated up to five days.  
After five days the radiochemical purity of          
125
I-F(ab’)2-nimotuzumab decreased to 78.53, 83.48 
and 87.37% when stored at room temperature, 37 
and 4 °C respectively. While the radiochemical 
purity of 
125
I-nimotuzumab decreased to 94.14, 
95.25 and 96.63% when stored at room temperature, 
37 and 4 °C respectively.  Based the above-
mentioned results appeared that both complexes, 
F(ab’)2-nimotuzumab and 
125
I-nimotuzumab, were 
relatively stable at 4 °C. 
 
 
CONCLUSION 
 
Nimotuzumab fragment, F(ab’)2-
nimotuzumab, with a purity of 94.7 %, had been 
sucssesfully prepared by fragmenting of intact 
nimotuzumab with pepsin for 14 hours and  
purification process by using a colomn 
chromatography. Radiolabeling of F(ab’)2-
nimotuzumab with 
125
I by using a iodogen as 
oxidator resulted 
125
I-F(ab’)2-nimotuzumab with 
radiochemical purity of 93.24% after a purification 
process by using a colomn chromatography.  
Stability test results showed that 
125
I-F(ab’)2-
nimotuzumab as well as 
125
I-nimotuzumab retained 
their radiochemical purities when stored either at 4, 
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37 °C or room temperature for one day.  While 
either
 125
I-F(ab’)2-nimotuzumab or 
125
I-nimotuzumab 
was found relately stable when stored at 4 °C for    
up to five days. Radiochemical purity either         
125
I-F(ab’)2-nimotuzumab or 
125
I-nimotuzumab 
however decreased significantly when stored at 
room temperature and 37 °C for up five days. 
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